
Arthroplasty
IV tranexamic acid reduces blood loss and transfusion rate in primary THA
This report has been verified
by one or more authors of the
original publication.
Orthopedics. 2016 Sep 1;39(5):e883-92
Sixteen randomized controlled trials (RCTs) were included in this meta-analysis evaluating the efficacy and safety of intravenous tranexamic acid in total hip arthroplasty. All included trials were placebo controlled. Results demonstrated significantly lower blood loss - including intraoperative blood loss, postoperative blood loss, and total blood loss - and transfusion rate with IV TXA versus placebo. The incidence of deep vein thrombosis was significantly higher following administration of IV TXA, but no significant differences between IV TXA and placebo were found for the rate of pulmonary embolism.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.